Ensign Peak Advisors
KDNY

Ensign Peak Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ensign Peak Advisors’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-359,480
Closed -$13.8M – 1785
2023
Q2 		$13.8M Sell
359,480
-2,358
-0.7% -$60.6K 0.03% 348
2023
Q1 		$8.38M Hold
361,838
– – 0.02% 445
2022
Q4 		$9.48M Buy
361,838
+124,933
+53% +$2.77M 0.02% 427
2022
Q3 		$4.66M Buy
236,905
+50,808
+27% +$1.02M 0.01% 538
2022
Q2 		$3.25M Hold
186,097
– – 0.01% 643
2022
Q1 		$3.04M Hold
186,097
– – 0.01% 726
2021
Q4 		$3.04M Buy
186,097
+83,029
+81% +$1.18M 0.01% 821
2021
Q3 		$1.31M Hold
103,068
– – ﹤0.01% 1320
2021
Q2 		$1.46M Hold
103,068
– – ﹤0.01% 1285
2021
Q1 		$1.6M Buy
103,068
+33,580
+48% +$548K ﹤0.01% 1216
2020
Q4 		$1.1M Hold
69,488
– – ﹤0.01% 1367
2020
Q3 		$845K Buy
69,488
+51,416
+285% +$689K ﹤0.01% 1377
2020
Q2 		$209K Buy
+18,072
New +$249K ﹤0.01% 1577

Ensign Peak Advisors's KDNY Position: Q3 2023 in Review

Ensign Peak Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 359,480 shares — an estimated $13.8M sold.

Ensign Peak Advisors first reported a position in KDNY in Q2 2020 and held it in 13 quarters. The position peaked at $13.8M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Ensign Peak Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 359,480 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $13.8M.
  • Ensign Peak Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2020 and held it in 13 quarters.
  • Ensign Peak Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $13.8M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.